Court invalidates Bayer erectile dysfunction patent

A federal appeals court invalidated a Bayer AG patent on its erectile dysfunction treatment Staxyn, paving the way for Teva Pharmaceutical Industries to launch a generic version of the drug, according to a Reuters report.

The report said US Court of Appeals for the Federal Circuit reversed a lower court decision in finding invalid on obviousness grounds a Bayer patent relating to Staxyn’s formulation that expires in 2028.